AU2009279458B2 - Long-acting DNA dendrimers and methods thereof - Google Patents

Long-acting DNA dendrimers and methods thereof Download PDF

Info

Publication number
AU2009279458B2
AU2009279458B2 AU2009279458A AU2009279458A AU2009279458B2 AU 2009279458 B2 AU2009279458 B2 AU 2009279458B2 AU 2009279458 A AU2009279458 A AU 2009279458A AU 2009279458 A AU2009279458 A AU 2009279458A AU 2009279458 B2 AU2009279458 B2 AU 2009279458B2
Authority
AU
Australia
Prior art keywords
dna
dendrimer
another embodiment
dna dendrimer
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009279458A
Other languages
English (en)
Other versions
AU2009279458A1 (en
Inventor
Robert C. Getts
James M. Kadushin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Code Biotherapeutics Inc
Original Assignee
Code Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Code Biotherapeutics Inc filed Critical Code Biotherapeutics Inc
Publication of AU2009279458A1 publication Critical patent/AU2009279458A1/en
Application granted granted Critical
Publication of AU2009279458B2 publication Critical patent/AU2009279458B2/en
Assigned to CODE BIOTHERAPEUTICS, INC. reassignment CODE BIOTHERAPEUTICS, INC. Request for Assignment Assignors: GENISPHERE, LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
AU2009279458A 2008-08-08 2009-08-10 Long-acting DNA dendrimers and methods thereof Active AU2009279458B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18831808P 2008-08-08 2008-08-08
US61/188,318 2008-08-08
PCT/US2009/053264 WO2010017544A2 (en) 2008-08-08 2009-08-10 Long-acting dna dendrimers and methods thereof

Publications (2)

Publication Number Publication Date
AU2009279458A1 AU2009279458A1 (en) 2010-02-11
AU2009279458B2 true AU2009279458B2 (en) 2015-07-02

Family

ID=41664237

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009279458A Active AU2009279458B2 (en) 2008-08-08 2009-08-10 Long-acting DNA dendrimers and methods thereof

Country Status (7)

Country Link
US (1) US20120122800A1 (https=)
EP (2) EP2657342B1 (https=)
JP (1) JP5583667B2 (https=)
AU (1) AU2009279458B2 (https=)
CA (1) CA2731521C (https=)
IL (1) IL210841A (https=)
WO (1) WO2010017544A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206611A1 (en) 2010-02-24 2011-08-25 Genisphere, Llc DNA Dendrimers as Thermal Ablation Devices
WO2012172546A1 (en) 2011-06-15 2012-12-20 Zak Naomi B Target-recognition compositions comprising novel synthetic conjugates for trapping and diagnosis of a target molecule
EP2773431B1 (en) * 2011-10-25 2019-03-20 Arch Personal Care Products, L.P. Composition containing an extract of a sequential or simultaneous fermentation
US9651549B2 (en) 2012-07-13 2017-05-16 Genisphere, Llc Lateral flow assays using DNA dendrimers
EP2950825B1 (en) * 2013-02-01 2019-09-11 Genisphere, LLC Functionalized dna dendrimers for gene delivery to cells
US20160051693A1 (en) 2013-03-21 2016-02-25 Genisphere, Llc Cellular Delivery of DNA Intercalating Agents
EP3289084B1 (en) * 2015-04-17 2020-09-16 Genisphere, LLC siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
EP3416671A4 (en) * 2016-02-19 2019-10-30 Genisphere, LLC NUCLEIC ACID CARRIER AND THERAPEUTIC METHODS OF USE
AU2017221437A1 (en) * 2016-02-19 2018-08-23 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US20190269728A1 (en) 2018-03-02 2019-09-05 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
WO2019216413A1 (ja) * 2018-05-11 2019-11-14 中国塗料株式会社 防汚塗料組成物、防汚塗膜、防汚塗膜付き基材及び防汚方法
WO2021053405A2 (en) 2019-08-30 2021-03-25 Sixfold Bioscience Ltd. Compositions for transfer of cargo to cells
CA3144528A1 (en) * 2019-12-23 2021-07-01 Illumina, Inc. Nanoparticle with single site for template polynucleotide attachment
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
CN115997016A (zh) 2020-04-27 2023-04-21 西克斯福德生物科学有限公司 包含具有模块化官能团的核酸纳米颗粒的组合物
EP4150065A2 (en) 2020-05-12 2023-03-22 Illumina Inc Generating nucleic acids with modified bases using recombinant terminal deoxynucleotidyl transferase
KR20230084520A (ko) * 2020-10-09 2023-06-13 스미토모 파마 가부시키가이샤 올리고 핵산 콘쥬게이트
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
EP4703381A1 (en) 2024-09-03 2026-03-04 Institució Catalana de Recerca i Estudis Avançats Antibodies against icam-1 and applications thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147526A1 (en) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5175270A (en) 1986-09-10 1992-12-29 Polyprobe, Inc. Reagents for detecting and assaying nucleic acid sequences
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6117631A (en) 1996-10-29 2000-09-12 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
WO1999006595A1 (en) 1997-07-29 1999-02-11 Polyprobe, Inc. Dendritic nucleic acids exhibiting maximal self-assembly
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023248A1 (en) * 2001-12-07 2004-02-05 Whitehead Institiute For Biomedical Research Methods and reagents for improving nucleic acid detection
EP1530581A4 (en) * 2002-06-12 2006-08-30 Datascope Investment Corp POLYMERIC MARKING MOLECULES
US7223544B2 (en) * 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20080199960A1 (en) * 2004-05-13 2008-08-21 Juliano Rudolph L Methods for the Delivery of Oligomeric Compounds
EP1891216B1 (en) * 2005-05-25 2012-02-22 The University Of York Hybrid interfering rna
US20100136614A1 (en) * 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147526A1 (en) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Genisphere: "Starfish (TM) fluorescent in situ detection kit", 2000 [retrieved from internet on 13/11/2014] *
Kadushin J.M. & Getts L.A.: " Enhancement of sensitivity in Luminex protein detection assays via dendrimer dependent signal amplification", Luminex Planet xMAP conference, April 25-27, 2005 *

Also Published As

Publication number Publication date
EP2320953B1 (en) 2015-07-15
EP2657342A1 (en) 2013-10-30
AU2009279458A1 (en) 2010-02-11
EP2657342B1 (en) 2015-11-18
JP2011530537A (ja) 2011-12-22
CA2731521A1 (en) 2010-02-11
EP2320953A2 (en) 2011-05-18
US20120122800A1 (en) 2012-05-17
CA2731521C (en) 2018-04-10
WO2010017544A2 (en) 2010-02-11
IL210841A0 (en) 2011-04-28
IL210841A (en) 2016-05-31
JP5583667B2 (ja) 2014-09-03
WO2010017544A3 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
AU2009279458B2 (en) Long-acting DNA dendrimers and methods thereof
JP7832771B2 (ja) デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド
CN102231979B (zh) 基因沉默治疗剂的脂质体有效递送方法和组合物
CA2860527C (en) High-efficiency nanoparticle-type double-helical oligo-rna structure and method for preparing same
CA2859127C (en) Novel oligonucleotide conjugates and use thereof
KR20230059845A (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
IL267246B2 (en) Exon-skipping oligomer conjugates for muscular dystrophy
IL267245B2 (en) Exon skipping oligomer conjugates for muscular dystrophy
IL267244A (en) Oxygen couplers skip axon for muscular dystrophy
AU2018336569A1 (en) Exon skipping oligomer conjugates for muscular dystrophy
Avitabile et al. Incorporation of naked peptide nucleic acids into liposomes leads to fast and efficient delivery
IL278966B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
WO2019209764A2 (en) Exon skipping oligomers and oligomer conjugates for muscular dystrophy
US20130108686A1 (en) Method for the delivery of oligonucleotides
JP6368363B2 (ja) デングウィルス特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含むデングウィルス増殖抑制用組成物
JP7306653B2 (ja) 構造強化されたＳ－ＴｕＤを用いた新規がん治療法
IL283646B2 (en) Exon skipping oligomer conjugates for muscular dystrophy
US20250136979A1 (en) Methods and Compositions for Avoiding Off-Target Effects
US9320814B2 (en) Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
IL280299B2 (en) Exon skipping oligomers for muscular dystrophy
WO2019074071A1 (ja) 核酸分子発現の調節

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CODE BIOTHERAPEUTICS, INC.

Free format text: FORMER OWNER(S): GENISPHERE, LLC